| MDM2 Protein | |
|---|---|
| Gene | [MDM2](/genes/MDM2) |
| UniProt | Q00978 |
| PDB | 1EDT, 1Z7M |
| Mol. Weight | 55 kDa |
| Localization | Nucleus, cytoplasm |
| Family | MDM family, RING finger proteins |
| Diseases | [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [Cancer](/diseases/cancer) |
Mdm2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MDM2 (Mouse Double Minute 2) is the primary negative regulator of the tumor suppressor p53, making it a critical protein in controlling cell cycle, DNA repair, and apoptosis[1]. In the nervous system, MDM2 plays important roles in neuronal survival, differentiation, and response to various stresses relevant to neurodegeneration[2].
The MDM2 gene encodes a protein of 491 amino acids that functions as an E3 ubiquitin ligase. MDM2 is one of the most frequently amplified genes in human cancers, highlighting its importance in cell cycle control[3].
MDM2 contains multiple functional domains:
The N-terminal domain:
The central region:
The RING finger domain:
NLS sequences allow nuclear-cytoplasmic shuttling:
MDM2 is the major regulator of p53:
In neurons, MDM2 participates in:
MDM2 also targets other proteins:
MDM2 is implicated in AD:
In PD:
MDM2 is oncogenic when amplified:
Therapeutic strategies include:
The study of Mdm2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Momand et al. [MDM2 as p53 inhibitor (1992)](https://doi.org/10.1016/0092-8674(92). 1992. ↩︎
Marine et al. MDM2 and p53 in cancer (2020). 2020. ↩︎
Zhang et al. MDM2 in neuronal apoptosis (2018). 2018. ↩︎